🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Berlin
Clinical trial register · Germany

Clinical Trials in Berlin, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1584 Hamburg 889 Essen 760 Dresden 707 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca115 Charite University, Berlin, Germany93 Janssen Research & Development, LLC49 Eli Lilly and Company45 Novartis Pharmaceuticals45
Site location
Berlin1584 Hamburg889 Essen760 Dresden707 Heidelberg627
All 635 locations
Target enrolment
to

Trials with a site in Berlin

1584 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
NCT07181109High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk
DrugZilebesiran
Alnylam Pharmaceuticals
Phase 3
11,000
Aachen, Ahaus, Altenburg, Bad Homburg, Berlin, Brandenburg an der Havel, Bremen, Cologne
2025-09-22
Recruiting
Impella Pump Return Study to Analyze Deposits and Biomaterial in Used Pumps
NCT06765226Heart Failure
Abiomed Inc.
Observational
200
Heidelberg, Düsseldorf, Dresden, Leipzig, Berlin, Cologne, Essen
2025-09-21
Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
NCT07190209Chronic Obstructive Pulmonary Disease
DrugLunsekimig
Sanofi
Phase 3
942
Ahrensburg, Augsburg, Berlin, Darmstadt, Frankfurt, Frankfurt am Main, Hamburg, Leipzig
2025-09-16
Recruiting
Tezspire Cardiac Events PASS
NCT06951867Cardiovascular Events, MACE
DrugTezepelumab
AstraZeneca
Observational
16,640
Berlin
2025-09-15
Recruiting
Determination of the Prevalence of Unrecognized Heart Failure Among Patients at Risk in Urban Areas Across Germany Using CMR
NCT07185100Heart Failure With Preserved Ejection Fraction (HFPEF), Renal Dysfunction, Stage B Heart Failure
German Heart Institute
Observational
600
Berlin
2025-09-13
Recruiting
A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
400
Berlin, Bonn, Braunschweig, Bremen, Cologne, Düsseldorf, Essen, Freiburg im Breisgau
2025-09-13
Recruiting
VITAL: Vaccination, Immunity, Time-restricted Eating, Aging and Lifestyle
NCT07000708Vaccination, Immunosenescence, Metabolism
Charite University, Berlin, Germany
Not applicable
24
Berlin
2025-09-10
Recruiting
European Real-World Registry for Use of the Ion Endoluminal System
NCT06923774Pulmonary Nodule, Lung Cancer
Intuitive Surgical
Observational
1,200
Berlin, Hemer, Wiesbaden
2025-09-09
Recruiting
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
NCT07054190Breast Cancer
DrugsGiredestrant·Inavolisib·Ribociclib·Letrozole
Hoffmann-La Roche
Phase 2
120
Berlin, Dresden, Essen, Heidelberg, Paderborn, Schwerin
2025-09-09
Recruiting
Oxytocin-Augmented Group Psychotherapy for Patients With Schizophrenia - an Oxytocin-dose Comparison
NCT07265180Schizophrenia Spectrum Disorders (SSD)
Charite University, Berlin, Germany
Not applicable
120
Berlin
2025-09-08
Recruiting
Validation of Donor-Derived Cell-Free DNA (Dd-cfDNA) for Kidney Transplant Monitoring
NCT07060716Kidney Transplant Rejection, Cell-free DNA
Insight Molecular Diagnostics
Observational
125
Heidelberg, Berlin
2025-09-08
Recruiting
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
DrugsCasdatifan·Cabozantinib
Arcus Biosciences, Inc.
Phase 3
720
Berlin, Dresden, Essen, Frankfurt, Freiburg im Breisgau, Halle, Hanover, Heidelberg
2025-09-08
Recruiting
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
NCT07115745Refractory Autoimmune Diseases
DrugsTocilizumab·Fludarabine·Cyclophosphamide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
125
Düsseldorf, Kiel, Berlin, Dresden, Hamburg
2025-09-04
By invitation
An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)
NCT07161700Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
DrugGlyphAllo
Seaport Therapeutics
Phase 2
360
Berlin, Schwerin, Chemnitz
2025-09-02
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Aachen, Bad Homburg, Berlin, Dresden, Essen, Frankfurt, Freiburg im Breisgau, Greifswald
2025-09-02
Recruiting
Stimulation of Acupuncture Points in Female Patients With Multiple Sclerosis and Neurogenic Bladder Dysfunction
NCT07183683Neurogenic Bladder Dysfunction
Charite University, Berlin, Germany
Not applicable
150
Berlin
2025-09
Recruiting
SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment
NCT07145190Parkinson Disease
Bial - Portela C S.A.
Observational
90
Berlin, Bochum, Freiburg im Breisgau, Fulda, Hetzdorf, Osnabrück, Siegen, Sundern
2025-08-27
Recruiting
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
NCT06920004Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
DrugsEmpasiprubart·IVIG
argenx
Phase 3
218
Berlin, Kiel
2025-08-22
Recruiting
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
NCT07018700Episodic Migraine
DrugXeomin
Merz Therapeutics GmbH
Phase 3
990
Berlin, Frankfurt, Greifswald, Kassel, Kiel
2025-08-21
Recruiting
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
NCT07018713Chronic Migraine
DrugXeomin
Merz Therapeutics GmbH
Phase 3
780
Berlin, Frankfurt, Greifswald, Kassel, Kiel
2025-08-21
Recruiting
A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany
NCT07102368Inflammatory Bowel Disease, Colitis, Ulcerative, Crohn's Disease
Janssen-Cilag G.m.b.H
Observational
500
Berlin
2025-08-18
Recruiting
A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia
NCT07086976Autoimmune Haemolytic Anaemia
DrugRilzabrutinib
Sanofi
Phase 3
90
Berlin, Essen
2025-08-18
Recruiting
A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes
NCT07112339Diabetes Mellitus, Type 2
DrugInsulin icodec
Novo Nordisk A/S
Phase 4
586
Amberg, Bad Mergentheim, Bad Reichenhall, Berlin, Bünde, Daaden, Dortmund, Dresden
2025-08-15
Recruiting
SCORE Study: Comparing Surgery and Rigid Collar Treatment for Odontoid Fractures in Adults Over 70
NCT06961578Odontoid Fracture, Elderly
Technical University of Munich
Not applicable
322
Munich, Frankfurt am Main, Berlin, Aachen, Cologne, Dresden, Essen, Göttingen
2025-08-13
Recruiting
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
NCT07070232Advanced Solid Tumor
DrugsBNT326·Paroxetine·Itraconazole·Pumitamig
BioNTech SE
Phase 1/2
1,438
Berlin, Essen, Mainz, München, Tübingen
2025-08-12
Recruiting
Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study
NCT07264426Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
DrugEfgartigimod PH20
argenx
Observational
200
Berlin, Bochum, Cologne, Düsseldorf, Frankfurt, Giessen, Göttingen, Hamburg
2025-08-11
Recruiting
Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
NCT06988618Prurigo Nodularis
Galderma R&D
Observational
600
Karlsruhe, Erlangen, Rostock, Kiel, Ahaus, Berlin, Bielefeld, Haslach
2025-08-11
Active, closed
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
NCT07076199Diabetes Mellitus, Type 1
DrugsInsulin aspart·Insulin glargine·Insulin icodec
Novo Nordisk A/S
Phase 3
877
Bad Mergentheim, Bad Oeynhausen, Berlin, Bochum, Dresden, Eisenach, Essen, Gelnhausen
2025-08-11
Recruiting
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
NCT07094516Alzheimer's Disease
DrugVHB937
Novartis Pharmaceuticals
Phase 2
407
Berlin, München
2025-08-07
Recruiting
Intensive Care Unit-acquired Heart Failure in Critically Ill: the ICU-HF Study
NCT07094425Heart Failure, ICUAW
Charite University, Berlin, Germany
Observational
50
Berlin
2025-08-07
Recruiting
A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism
NCT07007793Primary Hyperaldosteronism
DrugBaxdrostat
AstraZeneca
Phase 3
250
Berlin, Düsseldorf, Kaiserslautern, München, Reinfeld (Holstein), Würzburg
2025-08-07
Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803Prostate Cancer
DrugsPrednisolone/Prednisone·Saruparib·Abiraterone
AstraZeneca
Phase 3
700
Augsburg, Berlin, Braunschweig, Cologne, Dresden, Duisburg, Düsseldorf, Essen
2025-08-06
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965Breast Cancer
DrugsPrifetrastat·Exemestane·Everolimus·Fulvestrant
Pfizer
Phase 3
400
Ulm, Erlangen, Berlin, Hamburg
2025-08-05
Recruiting
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
NCT07075016Acute Myeloid Leukemia
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3
227
Berlin, Bochum, Bonn, Braunschweig, Bremen, Darmstadt, Flensburg, Freiburg im Breisgau
2025-08-05
Recruiting
Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy
NCT06113237Maternal Complications, Pregnancy Complication, Birth Outcomes, Adverse, Pregnancy
DrugCannabidiol
Jazz Pharmaceuticals
Observational
50
Berlin
2025-08-05
Recruiting
Study Evaluating the Effect of Humiome® Post LB on Stress, Anxiety, and Cognition in Aging Adults
NCT07110896Healthy Aging
dsm-firmenich Switzerland AG
Not applicable
236
Berlin
2025-08-01
Recruiting
Evaluation of Needs of Patients and Care-givers During and After Radiotherapy of Patients With Prostate Cancer
NCT07156903Prostate Cancer Patients
Charite University, Berlin, Germany
Not applicable
60
Berlin
2025-08-01
Active, closed
A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide
NCT07128550Viral Hepatitis
DrugsTobevibart·Elebsiran·Bulevirtide
Vir Biotechnology, Inc.
Phase 3
150
Berlin, Essen, Frankfurt am Main, Hanover
2025-07-30
Recruiting
Harmony TPV EMEA PMS
NCT06906926Severe Pulmonary Valve Regurgitation
Medtronic Cardiovascular
Not applicable
80
Bad Oeynhausen, Berlin, Leipzig, Munich
2025-07-30
Active, closed
A Registry on the FARAVIEW Technology of the OPAL HDx Mapping System When Used With the FARAWAVE NAV Ablation Catheter in the Treatment of Atrial Fibrillation
NCT06808217Atrial Fibrillation, Pulsed Field Ablation, FARAPULSE
Boston Scientific Corporation
Observational
550
Berlin, Frankfurt, Hamburg
2025-07-30
Recruiting
A Study With CIT-013 in RA Patients
NCT06567470Rheumatoid Arthritis
DrugsCIT-013 medium·CIT-013
Citryll BV
Phase 2
88
Bamberg, Berlin, München, Ratingen
2025-07-29
Recruiting
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433Atherosclerotic Cardiovascular Disease, Overweight, Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
12,800
Bad Homburg, Bad Krozingen, Bad Oeynhausen, Berlin, Bochum, Bonn, Detmold, Dortmund
2025-07-25
Recruiting
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
NCT05691244Acute Ischemic Stroke, Cerebral Stroke
DrugSovateltide
Pharmazz, Inc.
Phase 3
514
Altenburg, Göttingen, Rhein, Minden, Recklinghausen, Berlin, Bad Neustadt an der Saale, Erlangen
2025-07-24
Active, closed
Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma
NCT07120503Asthma (Diagnosis)
DrugWIN378
Windward Bio
Phase 2
136
Berlin, München, Bendorf, Lübeck, Darmstadt, Frankfurt am Main, Leipzig, Mainz
2025-07-24
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
DrugsVicadrostat·Dapagliflozin
Boehringer Ingelheim
Phase 3
11,800
Bad Homburg, Bad Krozingen, Bad Oeynhausen, Berlin, Bochum, Bremen, Bruchsal, Coburg
2025-07-22
Recruiting
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT06943755Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
DrugsZanzalintinib·Everolimus
Exelixis
Phase 2/3
440
Berlin, Erlangen, Essen, Mainz, Marburg, Tübingen, Würzburg
2025-07-21
Recruiting
A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)
NCT07001280Hereditary Angioedemas
CSL Behring
Observational
200
Ulm, Frankfurt am Main, Hanover, Leipzig, Hamburg, Berlin
2025-07-21
Recruiting
Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma
NCT07057596Mestastatic Uveal Melanoma
DrugTebentafusp
Grupo Español Multidisciplinar de Melanoma
Phase 2
19
Berlin
2025-07-18
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
NCT07093463Microbiome Dysbiosis, Gut Health
dsm-firmenich Switzerland AG
Not applicable
90
Berlin
2025-07-18
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
DrugsNeladalkib·Alectinib
Nuvalent Inc.
Phase 3
450
Berlin, Esslingen am Neckar, Großhansdorf, Immenhausen, Velbert
2025-07-17
Recruiting
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
NCT06997497Colon Adenocarcinoma, Rectal Adenocarcinoma
DrugsBevacizumab biosimilar·Calderasib·Adrucil·Cetuximab
Merck Sharp & Dohme LLC
Phase 3
477
Essen, Berlin, Hamburg
2025-07-16
Recruiting
Implantation of Engineered Cartilage Grafts for Treatment of Patellofemoral Osteoarthritis Versus Surgical Comparators.
NCT06576583Patellofemoral Osteoarthritis
DrugN-Tec
University Hospital, Basel, Switzerland
Phase 2
150
Berlin, Würzburg
2025-07-15
Active, closed
A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis
NCT07105488Atopic Dermatitis (AD)
DrugBFB759
Bluefin Biomedicine, Inc.
Phase 2
225
Bad Bentheim, Berlin, Göttingen, Heidelberg, Münster
2025-07-15
Recruiting
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
NCT06988605Atopic Dermatitis
Galderma R&D
Observational
1,000
Karlsruhe, Langenau, Augsburg, Erlangen, Regensburg, Remscheid, Ahaus, Berlin
2025-07-14
Active, closed
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
NCT07015983Lupus Erythematosus, Systemic, Lupus Nephritis
DrugsZola-cel·Fludarabine·Cyclophosphamide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
89
Leipzig, Magdeburg, Berlin, Cologne, Erlangen, Herne
2025-07-14
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
NCT06976216Alzheimer's Disease
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
586
Mannheim, Münster, Mainz, Berlin, Aachen, Bremen, Hamburg, Munich
2025-07-14
Recruiting
A Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care.
NCT06832722Shock, Cardiogenic
4TEEN4 Pharmaceuticals GmbH
Phase 1/2
90
Berlin, Freiburg im Breisgau, Hamburg, Leipzig, Mannheim
2025-07-13
Recruiting
An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria
NCT06927999Urticaria Chronic
DrugEpinephrine
ARS Pharmaceuticals, Inc.
Phase 2
42
Berlin
2025-07-09
Recruiting
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
NCT07076407Major Depressive Disorder
DrugAzetukalner
Xenon Pharmaceuticals Inc.
Phase 3
450
Berlin, Rosenheim
2025-07-08
Recruiting
A Randomized Controlled Study of the NEURESCUE Device as an Adjunct to Advanced Cardiac Life Support
NCT06793033Cardiac Arrest (CA), Cardiopulmonary Arrest
neurescue
Not applicable
84
Berlin, Heidelberg
2025-07-07
Recruiting
Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC
NCT07145450PDAC
Anocca AB
Phase 1/2
96
Berlin, Dresden, Heidelberg, Leipzig, München, Tübingen
2025-07-03
Recruiting
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT07052903Transthyretin Amyloidosis With Cardiomyopathy
DrugNucresiran
Alnylam Pharmaceuticals
Phase 3
1,750
Berlin, Cologne, Dresden, Göttingen, Hanover, Heidelberg, Leipzig, Magdeburg
2025-07-02
Recruiting
Preoperative Fasting and the Gut Microbiome Before Hip Replacement
NCT07651462Hip Osteoarthritis, Arthroplasty, Replacement, Hip, Postoperative Complications, Surgical Wound Infection
Charite University, Berlin, Germany
Not applicable
130
Berlin
2025-07-01
Recruiting
Study to Evaluate Long-term Effectiveness and Safety, Patient Characteristics and Subjective Patient-reported Outcomes of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Under Real-world Conditions
NCT07052396Chronic Obstructive Pulmonary Disease (COPD)
DrugDupilumab
Sanofi
Observational
350
Auerbach, Augsburg, Bad Homburg, Berlin, Burgwedel, Darmstadt, Erkelenz, Flensburg
2025-07-01
Recruiting
Effects of the Clinical Application of Traditional, Complementary and Integrative Medicine (TCIM) Procedures During Inpatient Stays in Germany
NCT07040475Chronic Disease
Charite University, Berlin, Germany
Observational
2,500
Bamberg, Berlin, Essen
2025-07-01
Recruiting
A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy
NCT06979375Heart Failure
DrugCDR132L
Novo Nordisk A/S
Phase 2
200
Berlin, Dresden, Essen, Frankfurt am Main, Halle, Hanover, Heidelberg, Kiel
2025-06-30
Active, closed
Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment Options
NCT06794554Chronic Pulmonary Aspergillosis
Mundipharma Research Limited
Phase 2
60
Berlin, Cologne, Gauting
2025-06-30
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
DrugsEpirubicin·Xeloda·Adriamycin·Paraplatin
Merck Sharp & Dohme LLC
Phase 3
2,400
Erlangen, Munich, Paderborn, Koblenz, Saarbrücken, Berlin
2025-06-30
Active, closed
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
NCT06966453Breast Cancer, Breast Neoplasms
DrugDisitamab Vedotin
Pfizer
Phase 1/2
74
Essen, Dresden, Berlin, Leipzig
2025-06-30
By invitation
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT07007637Hidradenitis Suppurativa
DrugSonelokimab
MoonLake Immunotherapeutics AG
Phase 3
835
Halle, Augsburg, Bad Bentheim, Berlin, Bielefeld, Bochum, Bramsche, Darmstadt
2025-06-27
Recruiting
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
NCT07082738Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca
Phase 2
987
Ahrensburg, Bendorf, Berlin, Darmstadt, Halle, Hanover, Landsberg, Leipzig
2025-06-27
Recruiting
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
NCT06979362Heart Failure
DrugCDR132L
Novo Nordisk A/S
Phase 2
200
Berlin, Dresden, Essen, Frankfurt am Main, Halle, Hanover, Heidelberg, Kiel
2025-06-27
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
5,056
Bad Berka, Bad Neustadt an der Saale, Bad Segeberg, Berlin, Bonn, Detmold, Dresden, Düsseldorf
2025-06-25
Recruiting
IP-coated Revision Hip Implants
NCT06737809Peri-Prosthetic Joint Infection
Aesculap AG
Not applicable
268
Berlin
2025-06-25
Recruiting
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
NCT06846281Relapsing Multiple Sclerosis
DrugsRemibrutinib·Ocrelizumab
Novartis Pharmaceuticals
Phase 3
400
Berlin, Bochum, Erbach im Odenwald, Essen, Greifswald, Heidelberg, Münster, Ulm
2025-06-23
Recruiting
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
NCT06961214Pulmonary Disease, Chronic Obstructive
DrugDepemokimab
GlaxoSmithKline
Phase 3
960
Munich, Offenbach, Rheine, Bendorf, Berlin, Darmstadt, Essen, Fürstenwalde
2025-06-23
Active, closed
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
NCT06959225Hidradenitis Suppurativa
DrugRuxolitinib
Incyte Corporation
Phase 3
580
Berlin, Bochum, Darmstadt, Dresden, Erlangen, Hamburg, Lübeck
2025-06-23
Recruiting
Clinical Study on the Safety and Efficacy of the Minimally Invasive Ennovate® Method for Pedicle Screw Placement
NCT06960018Cervical Spine Disease, Pain, Postoperative
Aesculap AG
Not applicable
76
Aachen, Berlin, Freiburg im Breisgau
2025-06-20
Active, closed
A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease
NCT07048197Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 1/2
27
Freiburg im Breisgau, Göttingen, Cologne, Berlin, Ulm
2025-06-20
Recruiting
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
NCT07065240Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
DrugGlyphAllo
Seaport Therapeutics
Phase 2
360
Berlin, Schwerin, Bad Homburg, Chemnitz
2025-06-19
Active, closed
A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)
NCT07037771Homozygous Familial Hypercholesterolemia
Arrowhead Pharmaceuticals
Phase 3
70
Berlin
2025-06-17
Recruiting
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT06943872Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsSonrotoclax·Venclexta·Obinutuzumab·Venetoclax
BeOne Medicines
Phase 3
630
Berlin, Cologne, Dresden, Jena, Kiel, Mutlangen, München, Neubrandenburg
2025-06-11
Recruiting
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
NCT06340568Endometrial Cancer
DrugsDoxorubicin·Docetaxel·Paclitaxel
BioNTech SE
Phase 3
480
Berlin, Essen, Kassel, München, Tübingen
2025-06-10
Active, closed
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH
NCT07000136Heterozygous Familial Hypercholesterolaemia
DrugAZD0780
AstraZeneca
Phase 3
473
Berlin, Dresden, Leipzig
2025-06-10
Active, closed
Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
NCT06956235Hidradenitis Suppurativa
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 2
149
Frankfurt am Main, Berlin
2025-06-09
Recruiting
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
NCT06872892Bronchiectasis
DrugVerducatib
Boehringer Ingelheim
Phase 3
1,755
Aachen, Ahrensburg, Bamberg, Berlin, Bochum, Bonn, Cologne, Donaustauf
2025-06-09
Recruiting
ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT06902558Autosomal Dominant Polycystic Kidney Disease
Calico Life Sciences LLC
Phase 2
240
Heidelberg, Munich, Hanover, Cologne, Berlin
2025-06-09
Recruiting
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
NCT06872125Dravet Syndrome
DrugZorevunersen
Stoke Therapeutics, Inc
Phase 3
170
Berlin, Bonn, Frankfurt, Friedberg, Heidelberg, München
2025-06-04
Recruiting
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
NCT07000357Cardiovascular Disease
DrugAZD0780
AstraZeneca
Phase 3
15,100
Amberg, Bad Bevensen, Bad Friedrichshall, Bad Homburg, Bad Oeynhausen, Bechhofen, Berlin, Bielefeld
2025-06-04
Active, closed
A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy
NCT06821542Chronic Graft-versus-host-disease
DrugAxatilimab
Incyte Corporation
Phase 3
9
Aachen, Berlin, Cologne, Dresden, Erlangen, Frankfurt am Main, Freiburg im Breisgau, Göttingen
2025-06-04
Recruiting
Assessing Declined Liver Grafts With Normothermic Machine Perfusion to Reduce Transplant Waiting Time
NCT06874296Liver Transplantation, Liver Diseases, Surgery
Charite University, Berlin, Germany
Not applicable
186
Hamburg, Aachen, Bonn, Münster, Berlin, Hanover, München, Regensburg
2025-06-02
Recruiting
A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)
NCT06568627Venous Leg Ulcer (VLU)
DrugEscharEx
MediWound Ltd
Phase 3
216
München, Chemnitz, Berlin, Bochum, Dresden, Erlangen, Kiel
2025-06-01
Recruiting
Safety and Efficacy of Crofelemer in Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC)
NCT06904872Short Bowel Syndrome, Malabsorption Syndromes, Short Gut Syndrome, Post-Op Complication
DrugCrofelemer
Napo Therapeutics, S.p.A.
Phase 2
18
Aachen, Berlin, Essen, Hamburg, Rostock
2025-05-29
Active, closed
Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
NCT06931405Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
Blueprint Medicines Corporation
Phase 2
105
Berlin, Dresden, Frankfurt am Main, Hanover, Mainz, Tübingen
2025-05-28
Recruiting
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
NCT06780098Lung Neoplasm
DrugsR-DXd·Ifinatamab Deruxtecan·Taxotere·Docetaxel
Merck Sharp & Dohme LLC
Phase 2
144
Tübingen, Berlin
2025-05-28
Active, closed
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
NCT07000123Cardiovascular Disease
DrugAZD0780
AstraZeneca
Phase 3
3,103
Amberg, Bad Homburg, Berlin, Dresden, Essen, Falkensee, Frankfurt, Freiburg im Breisgau
2025-05-28
Recruiting
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
DrugsSPY001·SPY002·SPY003
Spyre Therapeutics, Inc.
Phase 2
645
Berlin, Brandenburg an der Havel, Dachau, Frankfurt am Main, Kiel, Leipzig, Munich, Ulm
2025-05-27
Recruiting
Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
NCT06941025Fabry Disease, Pregnancy, Pregnancy Complications
Chiesi Farmaceutici S.p.A.
Observational
10
Berlin
2025-05-23
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504Endometrial Cancer
DrugsSacituzumab tirumotecan·Docetaxel·Keytruda·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
1,123
Aachen, Trier, Saarbrücken, Leipzig, Jena, Berlin, Hamburg
2025-05-22
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
500
Berlin, Essen, Frankfurt am Main, Hanover, Leipzig, Mainz, Munich, Nuremberg
2025-05-22
Rows per page Showing 301–400 of 1584
Previous 2 3 4 5 6 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-germany/city/berlin?page=4

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,584 of those studies with a site in Berlin.

How many clinical trials are recruiting in Berlin?

844 of the 1,584 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 47 have not yet opened recruitment, 660 are active but closed to new participants, and 33 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.